JSJinho Shin

Jinho Shin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jinho Shin has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Molecular profiling of pancreatic acinar cell carcinoma and amphicrine‐like carcinoma: high frequency of homologous recombination deficiency and molecular heterogeneity

    by Chankyung Kim, Hyun‐Nam Yun, Deokhoon Kim, Byung‐Kwan Jeong, Jinho Shin, Changhoon Yoo, Dongwook Oh, Kyu‐Pyo Kim, Tae Jun Song, Ki Byung Song, et al.

    Background: The 6th edition of the WHO Classification of Digestive System Tumours distinguishes amphicrine‐like carcinomas (ALCs) from mixed neuroendocrine‐non‐neuroendocrine neoplasms (MiNENs). Acinar cell carcinomas (ACCs) with an intimately admixed and not separated neuroendocrine component comprising >30% of the tumour are classified as amphicrine‐like ACCs (AL‐ACCs). We characterised the genomic landscape of pancreatic ACCs and AL‐ACCs to validate current classification and identify therapeutic targets. Methods: Among 2,151 pancreatic biopsy and resection cases that underwent targeted next‐generation sequencing using the OncoPanel AMC v4.3 or v4.5 (DNA‐based hybrid capture, targeting 323 genes (v4.3) or 343 genes (v4.5)), eight ACCs, seven AL‐ACCs originally diagnosed as MiNENs under the 5th edition of the WHO classification scheme, and four neuroendocrine tumours (NETs) were identified, diagnosed between 2020 and 2026. Results: Homologous recombination deficiency (HRD)‐associated alterations, involving BRCA1/2 , ATM and FANCD2 , were identified in 87.5% (7/8) of ACCs and 29% of AL‐ACCs. One ACC had an ATRX nonsense mutation. Genomic heterogeneity was observed in molecular profiling of AL‐ACCs; two demonstrated a ‘true hybrid’ signature with co‐occurrence of lineage‐specific drivers: MEN1 deletion and splice site mutation (neuroendocrine‐associated), APC , SMAD4 and CTNNB1 alterations (exocrine‐associated). Two others exhibited ‘ACC‐like’ signatures, including missense BRCA1 and nonsense TP53 mutations and MDM4 and AKT3 amplifications, located on chromosome 1q, despite their neuroendocrine differentiation. Conclusions: Pancreatic ACCs frequently harbour HRD‐related alterations, suggesting potential for PARP‐inhibitor therapy. AL‐ACCs comprise molecularly heterogeneous groups, including true hybrid and ACC‐like patterns. Larger studies are required to elucidate the molecular distinction between true hybrid AL‐ACCs and those with single‐lineage alterations to refine their classification.

  • Open Access

    3-Dimensional reconstruction reveals frequent intraluminal growth of submucosal veins in surgically resected pT1 colorectal cancers

    by Jihyun Park, Mi-Ju Kim, Yeon Wook Kim, Byong-Wook Lee, Junyoung Shin, Jinho Shin, Chan-Gi Pack, Dong-Hoon Yang, Jihun Kim, In Ja Park, et al.

    Background: Although venous invasion (VI) is associated with distant metastasis and observed in >50% of pT2–4 colorectal cancers (CRCs), the role of VI in pT1 CRCs is not well-defined. Methods: Thirty-four surgically resected pT1 CRCs were reevaluated for 2-dimensional (2D) VI using hematoxylin and eosin (H&E)–stained slides with additional elastic and desmin immunohistochemical staining (cohort A). Additionally, 27 pT1 CRCs without knowing VI status were selected for 3-dimensional (3D) VI evaluation only (cohort B). All 61 cases (cohorts A and B) were studied in 3D using tissue clearing. Results: VI was detected more commonly in 3D (17/34, 50.0%) than in 2D H&E slide evaluation (9/34, 26.5%, p = .047). When VI was identified in 3D (27/61, 44.3%), the most common phase was that of intraluminal growth (22/27, 81.5%), followed by intravasation (7/27, 25.9%) and extravasation (5/27, 18.5%). E-cadherin expression was characterized in 3D in foci of VI and varied in each phase of invasion. Conclusions: All three phases were observed in VI of pT1 CRCs. The extravasation of neoplastic cells from foci of VI in pT1 CRC suggests that VI could be a route of intratumoral spreading in a subset of pT1 CRCs.

  • Open Access

    Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification

    by In Hye Song, Soomin Ahn, Hyung-Don Kim, Jeong-Hyeon Jo, Jinho Shin, Min-Hee Ryu, Young Soo Park

    Song IH, et al. J Gastric Cancer. 2026 Apr;26(2):202-218. https://doi.org/10.5230/jgc.2026.26.e7


  • Open Access

    Tie2 activator 4E2 ameliorates diabetic nephropathy and synergizes with dapagliflozin in a mouse model

    by Da Som Jeong, Soo Min Ko, Ji-Young Lee, Hyo-Jeong Han, Yerin Lee, Weon Sup Lee, Eun-Ah Lee, Woo-Chan Son, Jinho Shin

    Diabetic nephropathy (DN), a primary cause of end-stage renal disease, stems from hyperglycemia-induced vascular dysfunction and aberrant angiogenesis. Sodium-glucose cotransporter 2 inhibitors, such as dapagliflozin, improve glycemic control and provide renal protection yet fall short of fully halting DN progression. This study explores 4E2, a Tie2 receptor activator that mimics angiopoietin-1 to stabilize the vascular endothelium, as a novel DN therapy-both independently and in combination with dapagliflozin. In a streptozotocin (STZ)-induced DN mouse model (DBA/2J strain), male mice were treated with weekly intravenous 4E2, daily oral dapagliflozin, or a combination of both for 4 weeks following STZ administration. Dapagliflozin primarily reduced fasting blood glucose with modest renoprotective effects, whereas 4E2 significantly lowered kidney weight, blood urea nitrogen, and urinary albumin while elevating serum albumin, indicating greater renal protection. Histological analysis showed that 4E2 more effectively attenuated glomerular hypertrophy and lesions compared to dapagliflozin. Immunohistochemistry revealed that 4E2 markedly increased VE-cadherin and CD31 expression while decreasing PDGFR-β, reflecting enhanced endothelial stability and reduced vascular remodeling through Tie2-mediated mechanisms. Combination therapy synergistically enhanced these outcomes, achieving superior reductions in glucose levels, glomerular damage, and vascular pathology compared to either treatment alone. In contrast to anti-VEGF therapies, which can worsen proteinuria, 4E2-mediated Tie2 activation normalizes vascular stability without disrupting physiological angiogenesis, providing a safer therapeutic option. These findings establish 4E2 as a promising treatment for DN, especially when combined with dapagliflozin, by leveraging Tie2-driven stabilization and synergistic benefits to meet this critical unmet need.


  • Open Access

    Supplementary Data1 from Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer

    by Yeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, Hyung-Don Kim, Kyu-Pyo Kim, Jae Ho Jeong, Inkeun Park, Baek-Yeol Ryoo, Dong Ki Lee, Hye Jin Choi, et al.

    Supplementary Methods; Supplementary Figs. 1-6; Supplementary Tables 1-4.


  • Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as a Potential Biomarker for Immune Checkpoint Inhibitors in Patients with Biliary Tract Cancer

    by Yeong Hak Bang, Choong-Kun Lee, Kyunghye Bang, Hyung-Don Kim, Kyu-Pyo Kim, Jae Ho Jeong, Inkeun Park, Baek-Yeol Ryoo, Dong Ki Lee, Hye Jin Choi, et al.

    Purpose: Recently, anti-programmed cell death-1/anti-programmed cell death ligand-1 (anti-PD1/L1) immunotherapy has been demonstrated for its efficacy when combined with cytotoxic chemotherapy in randomized phase 3 trials for advanced biliary tract cancer (BTC). However, no biomarker predictive of benefit has been established for anti-PD1/L1 in BTC. Here, we evaluated tumor-infiltrating lymphocytes (TIL) using artificial intelligence-powered immune phenotype (AI-IP) analysis in advanced BTC treated with anti-PD1. Experimental Design: Pretreatment hematoxylin and eosin (H&E)–stained whole-slide images from 339 patients with advanced BTC who received anti-PD1 as second-line treatment or beyond, were employed for AI-IP analysis and correlative analysis between AI-IP and efficacy outcomes with anti-PD1. Next, data and images of the BTC cohort from The Cancer Genome Atlas (TCGA) were additionally analyzed to evaluate the transcriptomic and mutational characteristics of various AI-IP in BTC. Results: Overall, AI-IP were classified as inflamed [high intratumoral TIL (iTIL)] in 40 patients (11.8%), immune-excluded (low iTIL and high stromal TIL) in 167 patients (49.3%), and immune-desert (low TIL overall) in 132 patients (38.9%). The inflamed IP group showed a substantially higher overall response rate compared with the noninflamed IP groups (27.5% vs. 7.7%, P < 0.001). Median overall survival and progression-free survival were significantly longer in the inflamed IP group than in the noninflamed IP group (OS, 12.6 vs. 5.1 months; P = 0.002; PFS, 4.5 vs. 1.9 months; P < 0.001). In the TCGA cohort analysis, the inflamed IP showed increased cytolytic activity scores and IFNγ signature compared with the noninflamed IP. Conclusions: AI-IP based on spatial TIL analysis was effective in predicting the efficacy outcomes in patients with BTC treated with anti-PD1 therapy. Further validation is necessary in the context of anti-PD1/L1 plus gemcitabine–cisplatin.


  • Open Access

    Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures

    by Bokyung Ahn, Hee‐Sung Ahn, Jinho Shin, Eunsung Jun, Eun‐Young Koh, Yeon‐Mi Ryu, Sang‐Yeob Kim, Chang Ohk Sung, Ju Hyun Shim, JeongYeon Hong, et al.

    Background & Aims: Lymphocyte‐rich hepatocellular carcinoma (LR‐HCC) is largely unknown and a rare subtype of HCC with immune‐rich stroma. Tertiary lymphoid structures (TLS), frequently observed in LR‐HCC, are known to be prognostically significant in various malignancies; however, their significance in HCC remains unevaluated.Methods: Clinicopathologic data of 191 cases of surgically resected conventional HCC (C‐HCC, n = 160) and LR‐HCC (n = 31) were retrieved. Immunohistochemistry, multiplex immunofluorescence staining, RNA sequencing and proteomic analysis were conducted. Differences between the subtypes were statistically evaluated.Results: LR‐HCC was significantly correlated to larger tumour size, higher Edmondson–Steiner grade, presence of TLS and higher CD3‐, CD8‐ and FOXP3‐positive T cell, high PD‐1 and PD‐L1 expression (p < .001 for all) compared to C‐HCC. Patients with LR‐HCC exhibited significantly better overall survival (OS) (p = .044) and recurrence‐free survival (RFS) (p = .025) than C‐HCC. LR‐HCC demonstrated TLS signatures with significantly higher proteomic‐based immune scores in 14 of 17 types of tumour‐infiltrating immune cells. Furthermore, C‐HCC with secondary follicles, the most mature form of TLS, exhibited significantly better OS (p = .031) and RFS (p = .033) than those without. Across the global proteome, LR‐HCC was well‐differentiated from C‐HCC and a map of protein–protein interactions between tumour‐infiltrating lymphocytes and HCC in tumour microenvironment was completed.Conclusion: LR‐HCC is clinicopathologically and molecularly distinct and shows better prognosis compared to C‐HCC. Also, the presence of secondary follicle can be an important prognostic marker for better prognosis in both LR‐HCC and C‐HCC.


  • Open Access

    Unusual or Uncommon Histology of Gastric Cancer

    by Jinho Shin, Young Soo Park

    Shin J, et al. J Gastric Cancer. 2024 Jan;24(1):69-88. https://doi.org/10.5230/jgc.2024.24.e7